Lasmiditan: the first neurally acting anti-migraine drug

Sangeeta Bhanwra, Sonia S. Mahajan, Rajiv Kumar


Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5-HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.


Lasmiditan, 5-HT1F agonist, Migraine

Full Text:



Headache disorders. Available at: https://www.who. int/news-room/fact-sheets/detail/headache-disorders#:~:text=In%20the%20Global%20Burden%20of,disorders%20collectively%20were%20third%20highest. Accessed on 22 March 2021.

Global burden of disease study 2013 collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743-800.

Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8(1) 46-54.

FDA approves new treatment for adults with migraine. Available at: Food%20and%20Drug,or%20visual%20disturbance)%20in%20adults. Accessed on 22 March 2021.

Rimegepant Approved by FDA for the acute treatment of migraine in adults. Available at: %2027%2C%202020%2C%20the,orally%20disintegrating%20tablet%20(ODT). Accessed on 22 March 2021.

Neeb L, Meents J, Reuter, U. 5-HT1F Receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics. 2010;7: 176-182.

Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017;264:2031-39.

Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15:291-303

Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989-96.

Food and drug administration. Lasmiditan label. Available at: atfda_docs/label/2019/211280s000lbl.pdf. Accessed on 22 March 2021.

Liefaard L, Drenth H, Pilgrim A. Prediction of therapeutically effective dose of COL-144 based on relationship between plasma concentrations and headache response (poster). Cephalalgia. 2009;29:24-9.

Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788-801.

Loo LS, Plato BM, Turner IM, Case MG, Raskin J, Dowsett SA, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol. 2019;19:191.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine. Neurol. 2018;91(24):e2222-32.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7): 1894-904.

Tepper D. Lasmiditan for the acute treatment of migraine. Headache J Head Face Pain. 2020;60: 1225-6.

CoLucid Pharmaceuticals details phase 3 development strategy for lasmiditan to address major unmet needs in acute migraine therapy. Available at: Accessed on 16 March 2021.